%0 Journal Article
%T Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study.
%A Santos-García D
%A de Deus T
%A Cores C
%A Feal Painceiras MJ
%A Íñiguez Alvarado MC
%A Samaniego LB
%A López Maside A
%A Jesús S
%A Cosgaya M
%A García Caldentey J
%A Caballol N
%A Legarda I
%A Hernández-Vara J
%A Cabo López I
%A López Manzanares L
%A González-Aramburu I
%A Ávila A
%A Gómez-Mayordomo V
%A Nogueira V
%A Dotor García-Soto J
%A Borrué-Fernández C
%A Solano B
%A Álvarez Sauco M
%A Vela L
%A Escalante S
%A Cubo E
%A Mendoza Z
%A Pareés I
%A Sánchez Alonso P
%A Alonso Losada MG
%A López-Ariztegui N
%A Gastón I
%A Kulisevsky J
%A Seijo M
%A Valero C
%A Alonso Redondo R
%A Buongiorno MT
%A Ordás C
%A Menéndez-González M
%A McAfee D
%A Martinez-Martin P
%A Mir P
%A  
%J Mov Disord Clin Pract
%V 11
%N 7
%D 2024 Jul 15
%M 38747234
%F 4.514
%R 10.1002/mdc3.14056
%X <B>BACKGROUND: </B>Levodopa-induced dyskinesias (LID) are frequent in Parkinson's disease (PD).<BR><B>OBJECTIVE: </B>To analyze the change in the frequency of LID over time, identify LID related factors, and characterize how LID impact on patients' quality of life (QoL).<BR><B>METHODS: </B>PD patients from the 5-year follow-up COPPADIS cohort were included. LID were defined as a non-zero score in the item "Time spent with dyskinesia" of the Unified Parkinson's Disease Rating Scale-part IV (UPDRS-IV). The UPDRS-IV was applied at baseline (V0) and annually for 5 years. The 39-item Parkinson's disease Questionnaire Summary Index (PQ-39SI) was used to asses QoL.<BR><B>RESULTS: </B>The frequency of LID at V0 in 672 PD patients (62.4 ± 8.9 years old; 60.1% males) with a mean disease duration of 5.5 ± 4.3 years was 18.9% (127/672) and increased progressively to 42.6% (185/434) at 5-year follow-up (V5). The frequency of disabling LID, painful LID, and morning dystonia increased from 6.9%, 3.3%, and 10.6% at V0 to 17.3%, 5.5%, and 24% at V5, respectively. Significant independent factors associated with LID (P < 0.05) were a longer disease duration and time under levodopa treatment, a higher dose of levodopa, a lower weight and dose of dopamine agonist, pain severity and the presence of motor fluctuations. LID at V0 (β = 0.073; P = 0.027; R2 = 0.62) and to develop disabling LID at V5 (β = 0.088; P = 0.009; R2 = 0.73) were independently associated with a higher score on the PDQ-39SI.<BR><B>CONCLUSIONS: </B>LID are frequent in PD patients. A higher dose of levodopa and lower weight were factors associated to LID. LID significantly impact QoL.